-
Levothyroxine containing products – Biotin interference with lab tests
Jan 21, 2023, 00:00 -
PRAC meeting highlights 9-12 January 2023
Jan 9, 2023, 00:00 -
Amoxicillin – MIMS – Drug-induced enterocolitis syndrome (DIES)
Jan 1, 2023, 00:00 -
Janus Kinase inhibitors (JAKi) – MIMS – New risk minimisation measures
Jan 1, 2023, 00:00 -
Drug Safety Newsletter – Edition 110 – 21 December 2022
Dec 21, 2022, 00:00 -
Mifegyne 200mg tablets – Changes to prescribing information
Dec 20, 2022, 12:50 -
SGLT2 inhibitors – MIMS – Reminder of the associated risk of diabetic ketoacidosis
Dec 1, 2022, 00:00 -
Nurofen Plus – MIMS – Serious clinical harms with higher than recommended doses
Dec 1, 2022, 00:00 -
PRAC meeting highlights 28 November - 1 December 2022
Nov 28, 2022, 00:00 -
Veterinary medicines containing Zinc oxide – Withdrawal of marketing authorisation
Nov 24, 2022, 15:47 -
Phenylephrine Hydrochloride 10 mg/ml Solution for Injection or Infusion – Differences between phenylephrine hydrochloride and alternative authorised products
Nov 17, 2022, 12:59 -
Levonorgestrel – Updated dosing information and removal instructions
Nov 17, 2022, 00:00 -
Spikevax – Instructions for Correct dosing of Spikevax booster vaccines
Nov 14, 2022, 00:00 -
Chlormadinone acetate and nomegestrol acetate – Measures to minimise the risk of meningioma
Nov 11, 2022, 00:00 -
Drug Safety Newsletter – Edition 109 – 10 November 2022
Nov 10, 2022, 00:00 -
Imbruvica (ibrutinib) – New risk minimisation measures
Nov 3, 2022, 00:00 -
Xalkori (crizotinib) – Vision disorders and need for monitoring in paediatric patients
Nov 3, 2022, 00:00 -
Mavenclad (cladribine) – MIMS – New liver monitoring requirement
Nov 1, 2022, 00:00 -
Medicines containing 5-fluorouracil (i.v.) – Caution when interpreting blood uracil levels
Oct 24, 2022, 00:00 -
PRAC meeting highlights 24-27 October 2022
Oct 24, 2022, 00:00
